top of page
Our
Science
µMESH is realized through a soft lithography proprietary fabrication approach, which allows for the precise control of all geometrical, mechanical, and pharmacological attributes
µMESH enables the local delivery of powerful combination therapies, addressing major challenges such as systemic toxicity, poor brain penetrance, and tumor heterogeneity
Differently from injectable gels, µMESH does not fill the resected surgical cavity but conforms to the tumor margins, like a patch, delivering multiple therapeutic agents deep into the residual diseased tissue over the course of days, weeks and months
The therapeutic efficacy of µMESH has been demonstrated in four different orthotopic preclinical tumor models
µMESH delivers deeper into the malignant tissue
200 nm red fluorescence beads released from µMESH diffuse more uniformly and deeper into a dense tumor spheroid than free beads, lighting up in red the entire tumor mass
µMESH sustained drug release maximizes anti-tumor efficacy
In patient-derived models of high-grade gliomas, the sustained release of docetaxel-nanomedicines and diclofenac from µMESH boosts survival compared to multiple systemic administration of temozolomide (TMZ) and one-time intracranial injection of docetaxel/diclofenac-nanomedicines (L-SPNs)
µMESH pharmacological properties are finely tuned during microfabrication
The sustained release of a potent chemotherapeutic drug like docetaxel can be modulated during microfabrication between a slow release over the course of several months (180 days - lower curves) or a fast release during the first 2 weeks followed by a sustained release over the course of the remaining months (upper curves), aiming to improve anti-tumor efficacy.
bottom of page